BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical hol

Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday&#39

U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira so

Shares of Veradermics, Incorporated (NYSE: MANE - Get Free Report) have been assigned an average rat

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepar

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

Bamco Inc. NY increased its position in shares of Veradermics, Incorporated (NYSE: MANE) by 284.8% d

Veradermics, Incorporated (NYSE: MANE - Get Free Report) Director John Childs sold 100,000 shares of

Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consen

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical compan

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for h

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market o

Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price

Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in

Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 fo

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday&#3

Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial o

US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a B

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

Jefferies analyst Roger Song maintains Veradermics (NYSE:MANE) with a Buy and raises the price ta

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. Wh

LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outper

Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for al

Needham analyst Serge Belanger initiates coverage on Veradermics (NYSE:MANE) with a Buy rating an

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica

U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 gui

Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all

Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and rai

Veradermics (NYSE:MANE) reported quarterly losses of $(0.62) per share which beat the analyst consen

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Veradermics (NYSE:MANE) with a Ov

Citigroup analyst Geoff Meacham initiates coverage on Veradermics (NYSE:MANE) with a Buy rating a

Leerink Partners analyst Marc Goodman initiates coverage on Veradermics (NYSE:MANE) with a Outper

Jefferies analyst Roger Song initiates coverage on Veradermics (NYSE:MANE) with a Buy rating and

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss,